ライフサイエンスコーパス: HAQ

1 HAQ DI scores were used to assess the discriminant valid

2 HAQ score was strongly correlated with depression, pain,

3 HAQ scores (0-3 scale) indicated substantial disability

4 HAQ signaling represents a potential target for the phar

5 ance P < 0.001, COPM satisfaction P < 0.001, HAQ DI P = 0.02) and most work outcomes (RA WIS [P = 0.0

6 h scores from the KFT (rs = 0.48, P < 0.01), HAQ (rs = 0.79, P < 0.01), and all sections of the AHFT

7 ity were found to have 3 characteristics: 1) HAQ disability scores are high at disease onset rather t

8 e onset rather than gradually increasing; 2) HAQ disability increases very slowly over time (0.03 uni

9 is and a 31-question item bank, including 20 HAQ items, the 10-item HAQ-II was developed.

10 (<0.20) for all of the scales of the SF-36, HAQ DI, and SF-6D at 12 months.

11 effect, unadjusted, was a difference of 0.53 HAQ Disability units (scale 0-3) between 100% DMARD use

12 ted with a 2-fold increased odds of having a HAQ score > or =1.00 at 5 years.

13 Abnormal HAQ-DI scores may support patient claims of functional i

14 In early diffuse SSc, the self-administered HAQ-DI is therefore a valuable assessment of function th

15 y characterized 4-hydroxy-2-alkylquinolines (HAQs) previously identified for their antimicrobial acti

16 tions mediating 4-hydroxy-2-alkylquinolines (HAQs) signalling compounds biosynthesis, including 3,4-d

17 he synthesis of 4-hydroxy-2-alkylquinolines (HAQs), including the Pseudomonas quinolone signal (PQS).

18 mice expressing common human STING1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splen

19 We subsequently generated an HAQ knock-in mouse expressing a mouse equivalent of the

20 In multivariable analyses, HAQ and other patient self-report measures were signific

21 nce for equivalence for ACR20 since 2017 and HAQ-DI since 2016.

22 ith few exceptions, changes in the SF-36 and HAQ scores were different between patients who differed

23 Changes in the SF-36 and HAQ scores were more strongly related to changes in the

24 related significantly with the MOS SF-36 and HAQ, indicating good convergent validity.

25 ted with quartiles from the RADAR, AIMS, and HAQ, providing evidence for the validity of the generic

26 te and the disease-specific RADAR, AIMS, and HAQ.

27 The mean difference between the HAQ and HAQ-II scores was 0.02 units.

28 r smoked had significantly higher Larsen and HAQ scores than did those who lacked the gene and had ne

29 The median scores for the PCS, MCS, and HAQ DI were 36.9, 45.5, and 0.9, respectively.

30 idirectional variation in change in MRSS and HAQ DI score was seen across the spectrum of disease dur

31 ly important changes in the SF-36 scales and HAQ disability scores were determined, which will be use

32 omparison of changes in the SF-36 scales and HAQ scores was made between groups of patients known to

33 est explained by a model with skin score and HAQ-DI (R2 = 0.455).

34 and the tender joint count, DAS28 score, and HAQ score.

35 al remission was achieved (n = 295), average HAQ scores despite clinical remission increased progress

36 A baseline HAQ DI score of > or =1.0 predicted mortality over 4 yea

37 A baseline HAQ DI score of > or =1.0 was predictive of mortality (o

38 ived areas (P = 0.019, adjusted for baseline HAQ score, age, sex, and symptom duration).

39 r of treatment, after adjusting for baseline HAQ score, the patients with early RA who had never take

40 anding RA, even after adjusting for baseline HAQ scores.

41 to examine the relationship of the baseline HAQ DI score to morbidity, mortality, and visceral invol

42 t of the degree of functional disability (by HAQ and SF-36 physical summation scores).

43 on walking knee pain, overall joint pain (by HAQ), and general health status (by QWB) were not signif

44 AQ mice, however, had less fat mass than did HAQ or wild-type mice on a chow diet.

45 econd model compared the odds of disability (HAQ score > or =1.00) in treated and untreated patients,

46 Billions of modern humans have the dominant HAQ, AQ alleles.

47 ed quality of life (demonstrated by FACIT-F, HAQ DI, and SF-36 scores, respectively) and showed a tre

48 Results yielded a single-factor HAQ-DI score, which favored the current scoring system o

49 oved, with a decrease of 51-60% in TPs, FIQ, HAQ, and VAS scales, and in the number of prescribed dru

50 of recruitment to NOAR: beta coefficient for HAQ 0.13, 95% CI 0.03-0.23, and for DAS28 0.31, 0.12-0.4

51 disease progression than the WOMAC (SES for HAQ = 0.27; SES for WOMAC = -0.05).

52 teria, and 3) substituting grip strength for HAQ scores.

53 ty, and depression in the "patient-friendly" HAQ format.

54 Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research purposes is simple and reliab

55 Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research purpos

56 was associated with poorer general function (HAQ; P < 0.0001), more severe pain (P = 0.002), greater

57 Fifty-three percent of patients had HAQ-DI scores > or = 1.0 (signifying moderate-to-severe

58 In the multivariate analysis, higher HAQ scores were associated with depression, and Asians h

59 lower QWB-SA scores and significantly higher HAQ scores than family medicine patients with and withou

60 nsurance coverage was associated with higher HAQ scores for some ages.

61 tly and independently associated with higher HAQ scores, lower Short Form 36 health survey physical f

62 decreasing lean mass associated with higher HAQ scores.

63 Using B cells from homozygous HAQ carriers, we found, surprisingly, that HAQ/HAQ carri

64 uropeans whereas Africans have no homozygous HAQ individuals.

65 000 Genomes Project we found that homozygous HAQ individuals account for approximately 16.1% of East

66 However, HAQ-DI scoring has not been validated.

67 nset, moderate-severe functional impairment (HAQ-DI scores > or = 1.0) was frequent (53%) in this gro

68 corresponding mean changes from baseline in HAQ-DI score were -0.39 and -0.35, as compared with -0.1

69 The reductions from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacit

70 unt (P = 0.005) best explained the change in HAQ DI score over 2 years (R2 = 0.528).

71 disease (r = 0.52, P = 0.003), and change in HAQ disability scores (r = 0.42, P = 0.017).

72 The mean 3-year change in HAQ score was compared by IMD and social class, and inte

73 For the mean (95% CI) 3-year change in HAQ score, a significant interaction exists between IMD

74 The mean difference in HAQ change was most notable between the most deprived (I

75 There was also a significant difference in HAQ score change between patients of the highest (SCI an

76 There was only a modest fall in HAQ scores during pregnancy, with >25% of women having s

77 lted in significantly greater improvement in HAQ scores (P < or = 0.006) and SF-36 physical component

78 erage was associated with point increases in HAQ scores among the ages of 20 to 24 years (0.59 [99% C

79 oorly, explaining only 5% of the variance in HAQ disability scores.

80 pqsE expression and not only a deficiency in HAQs/PQS production.

81 Increased HAQ-DI scores at baseline were correlated with reduced f

82 ssment Questionnaire (HAQ) disability index (HAQ DI) and the physical component score of the Medical

83 h Assessment Questionnaire disability index (HAQ DI), patient's global assessment of disease activity

84 h Assessment Questionnaire-Disability Index (HAQ-DI) (ie, SMD, -0.22 to 0.22).

85 h Assessment Questionnaire disability index (HAQ-DI) (P = 0.0244) explained the change in skin score

86 h Assessment Questionnaire-Disability Index (HAQ-DI) (which ranges from 0 to 3, with higher scores in

87 h Assessment Questionnaire Disability Index (HAQ-DI) has been well received by the research and clini

88 h Assessment Questionnaire-Disability Index (HAQ-DI) score (scores range from 0 to 3, with higher sco

89 h Assessment Questionnaire Disability Index (HAQ-DI) score, and safety assessments.

90 h Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based

91 h Assessment Questionnaire-Disability Index (HAQ-DI) scores (which range from 0 to 3, with higher sco

92 h Assessment Questionnaire-Disability Index (HAQ-DI; scores range from 0 to 3, with higher scores ind

93 h Assessment Questionnaire disability index [HAQ DI]), and, for those who were employed, the rheumato

94 em bank, including 20 HAQ items, the 10-item HAQ-II was developed.

95 etween anti-CarP antibodies and longitudinal HAQ and DAS28 scores.

96 o achieved either MDA or remission had lower HAQ DI and radiographic scores compared with patients wh

97 ts who were taking OCs at baseline had lower HAQ scores over time than women who were not taking OCs

98 had used OCs before symptom onset had lower HAQ scores throughout followup than patients who had not

99 hose with higher metabolite levels had lower HAQ scores.

100 se during followup was associated with lower HAQ scores over time than no OC use during followup (mea

101 ociations between BMI and CRP (P < 0.001), M-HAQ scores (P = 0.005), and IL-6 concentrations (P = 0.0

102 modified Health Assessment Questionnaire (M-HAQ) and the physical function scale of the Medical Outc

103 modified Health Assessment Questionnaire (M-HAQ) and the Short Form 36 (SF-36) physical function sca

104 modified Health Assessment Questionnaire (M-HAQ) score was 0.6 +/- 0.4 in obese patients compared wi

105 Modified Health Assessment Questionnaire (M-HAQ) scores, demographic characteristics, and employment

106 lation between the latent variable and the M-HAQ was -0.87; between the latent variable and SF-36 phy

107 A latent variable derived from the M-HAQ, the SF-36 physical function scale, and the Steinbro

108 ed from -1.22 for fatigue to -0.03 for the M-HAQ.

109 3 for depression, and 0.73 +/- 0.5 for the M-HAQ.

110 Mean HAQ score was 0.52 units higher for subjects in the high

111 At year 10, mean HAQ score (SD) was 0.57 (0.56); 53% and 14% of patients

112 TLI-treated patients had lower mean HAQ scores at the time of TLI (2.0 versus 2.4; P = 0.000

113 The estimated population mean HAQ DI was 0.25 (95% confidence interval 0.22-0.28), and

114 Functional disability (the mean HAQ DI score) was significantly lower in patients who we

115 Over 10 years, mean HAQ scores were 0.69, 0.72, 0.64, and 0.58 in strategies

116 The median HAQ score was 1.125 (range 0-3).

117 Scleroderma Clinic have completed a modified HAQ annually.

118 Compared with the HAQ, modified HAQ, and Medical Outcomes Study Short Form 36 physical f

119 abatacept regimens resulted in improved MRI, HAQ, and SF-36 scores, with 10 mg/kg showing the greates

120 were reported by 23% of patients and normal HAQ scores by 16% of patients who completed these questi

121 I, 0.98 to 1.04; tau2 = 0.000) and change of HAQ-DI scores (14 RCTs with 5579 patients; SMD, -0.04; 9

122 -7.73) were the most important correlates of HAQ-DI scores > or = 1.0.

123 d to the group model, however, the course of HAQ disability became clearer, and 51% of the variance i

124 effect of disease duration on the course of HAQ disability in individual patients.

125 The course of HAQ disability was assessed in 32,525 observations (1,84

126 In some patients, the course of HAQ disability was either 1) chaotic (scores change with

127 The predominant determinants of HAQ disability in RA are disease activity, pain, and psy

128 atively little change in the distribution of HAQ scores from pregnancy to postpartum.

129 Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with on

130 We used mouse models of HAQ and AQ to investigate the underlying mechanism.

131 ling was used to examine the relationship of HAQ-DI scores to SSc skin and organ system involvement.

132 The reversibility of HAQ scores decreased with the duration of RA (median 100

133 e, biosynthesis, regulation, and activity of HAQs.

134 the biosynthesis of five distinct classes of HAQs, and establish the sequence of synthesis of these c

135 PhnAB synthase, is the primary precursor of HAQs and that the HAQ congener 4-hydroxy-2-heptylquinoli

136 models of the effect of disease duration on HAQ disability were found to have 3 characteristics: 1)

137 iations of appendicular fat and lean mass on HAQ were additive without significant interaction.

138 ct measure, measures of disability and pain (HAQ), and measures of psychological function (AIMS2).

139 es were physician's global assessment, pain, HAQ, patient's global assessment, and acute-phase reacta

140 nts with digital ulcers had worse RCS, pain, HAQ disability (overall, grip, eating, and dressing), ph

141 20% improvement, compared with 71% of paired HAQ observations.

142 In an individual patient, HAQ scores at trial entry represented both reversible an

143 subanalysis of 1092 ACPA-negative patients (HAQ 0.15, 0.02-0.29; DAS28 0.37, 0.11-0.63).

144 -standardized Healthcare Access and Quality (HAQ) index.

145 ncluded the Health Assessment Questionnaire (HAQ) (physical function), Short Form 36 health survey (S

146 hat for the Health Assessment Questionnaire (HAQ) (range 0-3), were developed (total, and for young a

147 d using the Health Assessment Questionnaire (HAQ) and clinical response was determined based on the A

148 th modified Health Assessment Questionnaire (HAQ) and quality of life (QoL) assessments were investig

149 ssed by the Health Assessment Questionnaire (HAQ) and the Short Form 36-item health profile (SF-36),

150 ores on the Health Assessment Questionnaire (HAQ) and the Short Form-36 (SF-36) health survey, the in

151 ndex of the Health Assessment Questionnaire (HAQ) as the measure of function.

152 ncluded the Health Assessment Questionnaire (HAQ) Disability and Discomfort Scales, 10-cm visual anal

153 d using the Health Assessment Questionnaire (HAQ) disability index (DI) and radiographic progression

154 he Stanford Health Assessment Questionnaire (HAQ) Disability Index (DI) at the second time point.

155 The Health Assessment Questionnaire (HAQ) disability index (DI) has been commonly used in rhe

156 The Health Assessment Questionnaire (HAQ) Disability Index (DI) was also an important risk fa

157 SF-36), the Health Assessment Questionnaire (HAQ) disability index (DI), and Mahler's dyspnea index,

158 (FACIT-F), Health Assessment Questionnaire (HAQ) Disability Index (DI), and Short Form 36 (SF-36) in

159 nction, the Health Assessment Questionnaire (HAQ) disability index (DI), and the MRSS were modeled ov

160 0), and the Health Assessment Questionnaire (HAQ) disability index (DI; range 0-3).

161 nths in the Health Assessment Questionnaire (HAQ) disability index (HAQ DI) and the physical componen

162 nd Stanford Health Assessment Questionnaire (HAQ) Disability Index at 5 visits.

163 vey and the Health Assessment Questionnaire (HAQ) disability index at baseline and 6-week followup as

164 The Health Assessment Questionnaire (HAQ) disability index was the strongest clinical predict

165 res for the Health Assessment Questionnaire (HAQ) disability index, were assessed.

166 .0001), and Health Assessment Questionnaire (HAQ) disability scores (r = 0.34, P = 0.03).

167 The Health Assessment Questionnaire (HAQ) has become the most common tool for measuring funct

168 nces in the Health Assessment Questionnaire (HAQ) score at baseline and 3 years by IMD or social clas

169 r RA, had a Health Assessment Questionnaire (HAQ) score collected, and had the RA-specific Disease Ac

170 n, and mean Health Assessment Questionnaire (HAQ) score.

171 details and Health Assessment Questionnaire (HAQ) scores were recorded annually.

172 int counts, Health Assessment Questionnaire (HAQ) scores, C-reactive protein (CRP) levels, and the Di

173 ts, and the Health Assessment Questionnaire (HAQ) were the main measures of disease activity.

174 mpleted the Health Assessment Questionnaire (HAQ), a self report of functional ability.

175 core on the Health Assessment Questionnaire (HAQ), and levels of an acute-phase reactant.

176 n using the Health Assessment Questionnaire (HAQ), and quality of life measurement using the RA Quali

177 ls: QWB-SA, Health Assessment Questionnaire (HAQ), Arthritis Impact Measurement Scales (AIMS), and Ra

178 aire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue

179 mpleted the Health Assessment Questionnaire (HAQ), the Arthritis Impact Measurement Scales 2 (AIMS2)

180 ndex of the Health Assessment Questionnaire (HAQ), the Nail Psoriasis Severity Index (NAPSI), the phy

181 ed with the Health Assessment Questionnaire (HAQ), the Valued Life Activities (VLAs), and the Short P

182 ed with the Health Assessment Questionnaire (HAQ), were explored for the total cohort and by sex, con

183 d using the Health Assessment Questionnaire (HAQ), with adjustment for age at symptom onset.

184 completed a Health Assessment Questionnaire (HAQ).

185 mpleted the health assessment questionnaire (HAQ).

186 ssed by the Health Assessment Questionnaire (HAQ).

187 ue from the Health Assessment Questionnaire (HAQ).

188 (DI) of the Health Assessment Questionnaire (HAQ); Disease Activity Score in 28 joints (DAS28); RA WI

189 ndex of the Health Assessment Questionnaire (HAQ-DI) was administered to 134 patients as they entered

190 ding to the Health Assessment Questionnaire [HAQ] disability index [DI]) and health-related quality o

191 al ability (Health Assessment Questionnaire [HAQ] score) and radiographic progression (Sharp-van der

192 , function (Health Assessment Questionnaire [HAQ] score), and RA quality of life (RAQoL) questionnair

193 disability (Health Assessment Questionnaire [HAQ]), and mood (Hospital Anxiety and Depression Scale [

194 ommon human STING1 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ~60% of East As

195 Project, we found that the R71H-G230A-R293Q (HAQ) MPYS allele frequency increased 57-fold in East Asi

196 The R71H-G230A-R293Q (HAQ) of TMEM173 is the second most common human TMEM173

197 Median (interquartile range) HAQ score was 0.625 (0.125-1.25) and was significantly h

198 Reliability of the RCS, HAQ pain and disability scales, and AIMS2 mood and tensi

199 The mean (+/-SD) HAQ-DI score at entry was 1.04 +/- 0.67.

200 The age-specific HAQ indices were the outcome measures.

201 ronmental risks to estimate the age-specific HAQ indices.

202 s cross-sectional study, the US age-specific HAQ scores for ages 15 to 64 years were low relative to

203 Age-specific HAQ scores for each state in 2010 and 2016 were regresse

204 For ages 15 years or older, the age-specific HAQ scores were 85 or greater for all ages in 3 states (

205 The US national age-specific HAQ scores were compared with high-income peers (Canada,

206 In 1990, US age-specific HAQ scores were similar to peers but increased less from

207 index modified for the spondylarthropathies (HAQ-S; range 0-3).

208 In addition to the standard HAQ questions about disability, the questionnaire includ

209 fter adjusting for age, sex, smoking status, HAQ score, RF positivity, and swollen joint counts (HR 3

210 We conclude that HAQ is a null TMEM173 allele.

211 NG1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING1-mediated cel

212 s HAQ carriers, we found, surprisingly, that HAQ/HAQ carriers express extremely low MPYS protein and

213 The HAQ DI (range of scores 0-3) was measured in a random sa

214 The HAQ DI correlated directly with skin involvement, sclero

215 The HAQ DI is a self-administered questionnaire that SSc pat

216 The HAQ DI score and total skin score at baseline were highl

217 The HAQ DI was correlated with pain (r = 0.58) and global se

218 The HAQ disability index and total knee score were more sens

219 The HAQ showed high internal consistency and high concurrent

220 The HAQ was repeated after 1, 2, 3, 5, 7, 10, 12, 15, and 20

221 The HAQ-DI scores (month 3) and DAS28-4(ESR) less than 2.6 r

222 The HAQ-II can be used in all places where the HAQ is now us

223 The HAQ-II is a reliable and valid 10-item questionnaire tha

224 The HAQ-II performed as well as the HAQ in a clinical trial

225 The HAQ-II was reliable (reliability of 0.88, compared with

226 The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4

227 The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (~10-fold

228 Although the HAQ DI score was heavily influenced by hand dysfunction

229 Although the HAQ is a useful clinical tool and a central measure of d

230 By Cox regression analysis, the HAQ DI was one of the best predictors of survival.

231 baseline vitamin D metabolite levels and the HAQ score; that is, those with higher metabolite levels

232 nnaire that performs at least as well as the HAQ and is simpler to administer and score.

233 The HAQ-II performed as well as the HAQ in a clinical trial and in prediction of mortality a

234 an irreversible component by associating the HAQ score during remission with 2 measures associated wi

235 The mean difference between the HAQ and HAQ-II scores was 0.02 units.

236 ls of physical disability as measured by the HAQ (P < 0.001).

237 ased burden of disability as measured by the HAQ and higher disease activity in patients with inflamm

238 proving physical function as measured by the HAQ DI over 24 months of treatment.

239 easured by GCSE grades and negatively by the HAQ DI score (t = 10.94, P = 6.36 x 10(-16) ).

240 ity/severity (particularly as defined by the HAQ DI) was important, smoking was the most consistent i

241 rted physical disability, as measured by the HAQ, occurs as a function of disease acting over time do

242 Consequently, the HAQ/HAQ B cells do not respond to CDNs.

243 n, mortality would be reduced by 50% for the HAQ and by 33% for global disease severity if patients i

244 rtaken to establish normative values for the HAQ DI in a general population and to analyze its correl

245 28 [CRP] of <2.6, 71.8% versus 66.8% for the HAQ DI, and 9.7 versus 10.6 and 7.3 versus 7.2, respecti

246 iability of 0.88, compared with 0.83 for the HAQ), measured disability over a longer scale than the H

247 placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score

248 Five original items from the HAQ were retained.

249 s study, the disability index (DI) (from the HAQ) and the VAS scores (on a 0-3 scale) were compared w

250 d validate a revised version of the HAQ (the HAQ-II).

251 However, the HAQ is long (34 questions, including 20 concerning activ

252 radiographic scores, but differences in the HAQ and RAQoL scores were maintained (P < 0.05).

253 hieved the MCID compared with placebo in the HAQ DI score (30.9% versus 14.8%), transitional dyspnea

254 n coefficient 0.368), as were changes in the HAQ DI score and the total skin score over 2 years (corr

255 Improvement in the HAQ DI score in these patients with diffuse scleroderma

256 d at 2 years, improvement (reduction) in the HAQ DI score over 2 years was related to factors other t

257 s well as the relationship of changes in the HAQ DI score to changes in physical examination, laborat

258 12 months and 24 months; improvement in the HAQ DI with LEF4(-0.60) was statistically significantly

259 ment for baseline scores, differences in the HAQ DI, SF-36 role physical, general health, vitality, r

260 ovement from baseline of at least 0.3 in the HAQ disability index (47.3 percent vs. 23.3 percent, P<0

261 A 1-SD change in the HAQ resulted in a much larger increase in the odds ratio

262 There were also greater reductions in the HAQ-DI score at month 3 and higher percentages of patien

263 The mean change in the HAQ-DI score was -0.35 in the 5-mg tofacitinib group and

264 y >6 times with each 1-point increase in the HAQ-S.

265 evelop and validate a revised version of the HAQ (the HAQ-II).

266 n mouse expressing a mouse equivalent of the HAQ allele (mHAQ).

267 ded within 3 months of administration of the HAQ and VAS, using t-tests and Spearman's correlation te

268 The normative values of the HAQ DI that we have presented could be used as a referen

269 d to groups of patients) explains 37% of the HAQ disability score variation.

270 Aspects of the HAQ's psychometric properties were evaluated.

271 as to examine the structural validity of the HAQ-DI and evaluate the latent factors underlying HAQ-DI

272 t study provides the first validation of the HAQ-DI scoring system as determined by its latent factor

273 ch favored the current scoring system of the HAQ-DI.

274 n large part the "floor effects" seen on the HAQ and MHAQ, and are useful to screen for problems with

275 ed for other major secondary end points (the HAQ and the SF-36), the NAPSI, the physician's global as

276 ar study from routine clinical practice, the HAQ was the most powerful predictor of mortality, follow

277 y Short Form 36 physical function scale, the HAQ-II was as well correlated or better correlated with

278 We studied the HAQ-II in 14,038 patients with rheumatic disease over a

279 ured disability over a longer scale than the HAQ, and had no nonfitting items and no gaps.

280 We propose that the HAQ and AQ alleles underwent a natural selection during

281 s the primary precursor of HAQs and that the HAQ congener 4-hydroxy-2-heptylquinoline (HHQ) is the di

282 We tested the concept that the HAQ has a reversible and an irreversible component by as

283 e ACR 20% response rates are higher when the HAQ, rather than grip strength, is used to measure physi

284 e HAQ-II can be used in all places where the HAQ is now used, and it may prove to be easier to use in

285 5 observations (1,843 patients) in which the HAQ was administered.

286 Prospective studies with the HAQ administered at regular intervals, as in controlled

287 tiffness scores were all associated with the HAQ disability index in RA (all r > 0.55, p 0.0002), but

288 d favorable measurement properties, with the HAQ having the advantages of being more sensitive to cha

289 relationship with 1,25(OH)(2)D was with the HAQ score.

290 Compared with the HAQ, modified HAQ, and Medical Outcomes Study Short Form

291 Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research purposes is s

292 ersion from HAQ to HAQ-II and from HAQ-II to HAQ for research purposes is simple and reliable.

293 I and evaluate the latent factors underlying HAQ-DI scoring.

294 Mean scores +/- SDs on instruments were: HAQ 0.73 +/- 0.69; MCS 49 +/- 12; and PCS 33 +/- 11.

295 versible and irreversible impairments, while HAQ scores at the time of RA remission represented the m

296 rall, the MRSS improves during trials, while HAQ DI scores and lung function are mostly static.

297 and social class and their association with HAQ scores (P = 0.001) to modify outcome: IMD1/SC I and

298 the strongest association per kilogram with HAQ.

299 nd positive associations were also seen with HAQ scores, but these did not meet statistical significa

300 s from more deprived areas had poorer 3-year HAQ outcome than those from less deprived areas (P = 0.0